News

The alliance will combine Clinigen’s and Cumberland’s respective strengths, expertise and geographical footprints to maximize the commercial potential of future products. As part of Clinigen’s continuing strategy to

his announcement was made at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, September 16-19, 2015 in New York, NY. VISTA (V-Domain Ig Suppressor of

Amgen has agreed to acquire all outstanding shares of Dezima for up to $1.55bn from Forbion and other current shareholders, subject to obtaining U.S. Federal Trade Commission clearance.

ALLDocs, also known as The Association of LensCrafters Leaseholding Doctors, is the second largest independent optometry group in the U.S. It works closely with its LensCrafters partners. "This

Under the terms of the agreement, CICT will utilize Cesca’s newest evolution of the AutoXpress® platform under the Company’s "Early Technology Access Program". Specifically, this latest innovation of

These formulations will be compared against an immediate release oral solution of drug candidate OCR-002 and ammonia-lowering agent glycerol phenylbutrate (RAVICTI®), a pre-pro drug of phenylacetate, a component

No adverse effects on cognition or emotional stability and no abuse potential were indicated with BNC210 reducing the effect of nicotine. The company enrolled 54 healthy volunteers and

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

The companies will advance new therapies that function via the ubiquitin proteasome system (UPS) for modulating protein homeostasis, a fundamental cellular process controlling protein levels. Celgene will pay